

# **Acotec Scientific Holdings Limited**

2025H1 Business Performance Review

Aug. 2025

**TRUSTED INNOVATION**  
FOR LIFE

## Legal Disclaimer

- This Presentation is strictly confidential and subject to the terms and conditions described below. It is only sent to some people and provided with information about Acotec Scientific Holdings Limited (the "Company") to help you decide whether to conduct in-depth research on the Company. The information contained in this Presentation has not been verified by any regulatory agency in any jurisdiction. The content of this Presentation (regardless of all or part of the content and regardless of the purpose) shall not be copied, distributed or shared directly or indirectly with any person (regardless of whether such person is a member of your company or group). In particular, neither the information contained in this Presentation nor any copy hereof may be, directly or indirectly, taken or transmitted into or distributed in the United States, Canada, Australia, Japan, Hong Kong, Singapore or any other jurisdiction which prohibits the same except in compliance with applicable securities laws. Any failure to comply with this restriction may constitute a violation of U.S. or other national securities laws. Anyone who obtains this Presentation should understand or be familiar with such restrictions.
- This Presentation and the information contained therein have not been independently verified and are not intended to constitute the basis for making investment decisions. The content of this Presentation does not constitute or form and shall not be construed as a solicitation of an offer for the sale or purchase of securities under any other jurisdiction. Any part of this Presentation does not constitute the basis of any contract or undertaking. Any decision to purchase the Company's securities in a public or private offering shall be based on the prospectus or international offering circular prepared by the Company for the relevant securities offering and any supplementary price information. This Presentation does not include any information or materials that would cause this Presentation to constitute (i) a prospectus under Section 2(l) of the Companies (Winding Up and Miscellaneous Provisions) (Cap.32 of Hong Kong) or the Securities Act of 1933 (as amended) (the "Securities Act"), or an advertisement in relation to a prospectus or proposed prospectus, or an extract from or abridged version of a prospectus under Section 38B of the Companies (Winding-up and Miscellaneous Provisions), or an advertisement, invitation or document which contains any advertisement or invitation under Section 103 of the Securities and Futures Ordinance (Cap. 571 of Hong Kong), or (ii) an invitation to the public made in Hong Kong without abiding by Hong Kong law or introducing exemptions under Hong Kong law. This Presentation is subject to change without notice.
- The Company's securities have not been and will not be registered under the Securities Act or the securities law of any state in the United States, and may not be offered or sold in the United States without registration or obtaining relevant applicable exemptions. Neither this Presentation nor its content constitutes or forms, and shall not be construed as part of an offer or solicitation of an offer to subscribe for securities in the United States. The Presentation shall not be carried or transmitted to the United States (including its territories and commonwealths, any state or the District of Columbia), or distributed directly or indirectly in the United States (including its territories and commonwealths, any state or District of Columbia). The Company's securities will not be offered or sold in the United States except for transactions that are not subject to exemptions under the provisions of the Securities Act or not subject to the Securities Act.
- By participating in or by reading this Presentation, you are recognized to have made representations and warranties to the Company, the parties involved in the Company's securities issuance, or their respective affiliates, controllers, directors, managers, partners, employees, agents, representatives or advisors that you and any you represent (if any) are either (i) a "qualified institutional buyer" (within the meaning of Rule 144A under the United States Securities Act of 1933, as amended), or (ii) outside the United States. You are also deemed to have represented and agreed that you and any customers you represent are professional investors as defined in the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and any rules made thereunder.
- The information in this Presentation is provided by the Company. This Presentation is not intended to be comprehensive or to contain all the information you may need to evaluate the Company. Regarding the accuracy, reliability, correctness, reasonableness, fairness or completeness of this Presentation or any information therein, or any oral or written communication regarding the evaluation of the Company, none of the parties (to avoid ambiguity, including but not limited to the Company, the parties involved in the Company's securities issuance, or their respective affiliates, controllers, directors, managers, partners, employees, agents, representatives or advisors) has or will make any express or implied statement or guarantee, and shall not, within the scope permitted by law, assume any liability arising therefrom. In particular, regarding the realization or reasonableness of any assumptions, speculations, goals, estimates or prospects contained in this Presentation, no express or implied statements or guarantees are made, nor should you rely thereon. Some of the information contained herein comes from different sources, including some third parties, and has not been independently verified by the Company. For the losses caused to you or any person using or relying on the information contained or disclosed in this Presentation, the Company, the parties involved in the Company's securities issuance, or their respective affiliates, controllers, directors, managers, partners, employees, agents or representatives shall take no responsibility (whether in negligence or otherwise). The use of registered trademarks, commercial trademarks and logos or photographic materials within this Presentation are exclusively for illustrative purposes and are not meant to violate the rights of the creators and/or applicable intellectual property laws.
- This Presentation is subject to the disclaimer and restrictive language contained therein. Any person shall make their independent evaluation and analysis, and shall not use any information mentioned, discussed or quoted in therein as the basis for their actions. You understand and assure the Company, the parties involved in the Company's securities issuance, or their respective affiliates, controllers, directors, managers, partners, employees, agents, representatives or advisors that you are a professional investor and have the knowledge, experience and ability required to evaluate the Company, you will make independent evaluation of the Company, its securities and all the information provided, and you have or will obtain independent advice for the evaluation of the Company's securities.
- This Presentation may contain the Company's current beliefs and expectations regarding the indicated future dates. Such forward-looking statements are based on some assumptions about the Company's operations or factors outside the Company's control, and may be affected by a number of known and unknown factors. Therefore, the Company's actual performance may be materially different from these forward-looking statements. You shall not rely on such forward-looking statements. The Company, the parties involved in the issuance of the Company's securities, or their respective affiliates, controllers, directors, managers, partners, employees, agents, representatives or advisors shall not be obliged to update or revise such forward-looking statements in response to new information, events or circumstances that occur after these dates.
- This Presentation and the information contained therein are strictly confidential. This Presentation and the information contained therein shall not be copied, reproduced, or transmitted to others in any form, or disclosed for any purpose (whether in whole or in part). Failure to comply with these restrictions may constitute a violation of the law and may result in legal or regulatory action. By receiving this Presentation or the information therein, you agree (1) that you have read and agree to abide by the requirements in this disclaimer; and (2) that you will keep the information contained in this Presentation strictly confidential.
- By participating in and accepting this Presentation, you agree to maintain the absolute confidentiality of the information contained in this Presentation and accept the restrictions and other conditions stated therein. Failure to comply with these restrictions and conditions may violate relevant laws and regulations and result in legal or regulatory measures.



**2025H1 Financial  
Performance Review**



**The Progress of CCT  
Implementation**



**Product  
Commercialization**



**R&D, Product  
Approvals, and  
Manufacturing Status**



**Q&A**

**01**

# **2025H1 Financial Performance Review**


For Investors' Reference Only



The business sustained rapid growth while achieving a more diversified income sources

(In millions RMB)

(In millions RMB)




- In 2025 H1, the company's business continued to grow steadily, with total revenue reaching **RMB 351 mn**, a yoy increase of **20.1%**.
- Revenue from **peripheral DCBs** amounted to **RMB 176 mn**.
- Revenue from **Venous Intervention, vascular access, and other business** was **RMB 176mn, up 49.2% yoy**. Thanks to the continuous increase in the penetration rate of the company's products and the approval of several new products, the company's sources of income have become more diversified, driving rapid growth in this part of the business and increasing **its revenue share to 50%**.



Gross Profit & Gross Profit Margin

(In millions RMB)



- 2025 H1 **Gross Profit**: RMB 261 mn
- 2025 H1 **Gross Margin**: 74.2%, consistent with the same period in 2024
- Key Drivers for top-tier gross margin: 1) Continuous optimization of gross margin for venous and access products after volume ramp-up; 2) DCB products, which have been commercialized for over 10 years, have maintained a good gross margin level; 3) Implementation of cost-reduction and efficiency-improvement measures, including replacing purchased raw materials with self-produced ones and optimizing production processes.





## R&D expenses

(In millions RMB)

▲ % of Sales  
■ R&D Expenses




- In 2025H1, R&D expenses amounted to approximately **RMB 102 mn**, reflecting a modest yoy increase of around 2% in absolute terms, while the R&D expense ratio declined. The company remains focused on tracking clinical and market needs, initiating new projects, and advancing key R&D and registration activities globally, thereby strengthening the foundation for future growth.
- The **R&D expense ratio fell to about 29%, compared to 34% in 2024H1**, largely driven by strong revenue expansion and increasing benefits from platform synergies.



## Selling and distribution expenses

(In millions RMB)

▲ % of Sales  
■ Selling and Distribution Expenses




- Sales and distribution expenses in 2025H1 reached approximately **RMB 56 mn**, rising 11.6% yoy. This increase was primarily due to **expanded market outreach and academic activities following several new product launches**, which were aimed at enhancing physician and patient education, elevating brand presence, and boosting product recognition to sustain competitive advantage.
- The **sales expense ratio declined to 16%**, as a result of robust revenue growth.



## Administrative expenses

(In millions RMB)

▲ % of Sales  
■ Administrative Expenses




- 2025H1 saw further benefits from the company's ongoing operational streamlining. Administrative expenses totaled **RMB 38 mn**, accounting for 10.8% of revenue—**maintaining an efficient and stable level**.



## Net Profit & Adjusted Net Profit

(In millions RMB)



- In 2025H1, the Company achieved a **net profit** of **RMB 88.58 mn**, representing a year-on-year increase of 121.7%, with a net profit margin of 25%.
- Excluding approximately RMB 5.54 mn in exchange losses and around RMB 5.45 mn in one-time share-based payment, the company delivered an **adjusted net profit** of approximately **RMB 99.57 mn**, up 151% year on year.
- The Company demonstrated strong business growth with an increasingly diversified revenue structure as more products were launched. Effective cost optimization and precision management measures further contributed to accelerated profitability.



## Liquidity and Financial Resources



- As of the end of 2025H1, the Company's available financial resources totaled approximately **RMB 1 billion**.
- Sufficient cash reserves ensure stable operations and support business development opportunities.

02

# The Progress of CCT Implementation

For Investors' Reference Only



# Key Updates on Collaboration with BSC: Product Commercialization

TRUSTED INNOVATION  
FOR LIFE

## Global Expansion Landscape of Collaborative Products

With the launch of products in China and globally, the scope and geographical coverage of collaboration are continuing to expand.

### Overseas Countries



SFA DCB  
AcoArt Orchid®



BTK DCB  
AcoArt Tulip® & Litos®

- **Distribution Agreement signed for SFA & BTK DCB sales in overseas markets in 2023.**
- Acotec has been actively progressing through the regulatory registration and market access processes in various overseas countries.

**Peripheral DCBs are expected to be launched in the following countries in 2025:**



Canada



United Kingdom



Belgium



Ireland



Norway



Denmark



Hungary



Colombia



Singapore

### Hong Kong, China and Taiwan, China



PI+Coronary  
Products

- **In 2025, Acotec and BSC continued to advance their cooperation on the commercialization of multiple peripheral and coronary products in Hong Kong and Taiwan, China.**

### The Mainland China

- Distribution Agreement signed for Approved Coronary Products, BSC has commenced selling Acotec's products in the mainland China market.
- The collaboration scope will continue to broaden with the approval of more products in the future.



PTCA Balloon  
YAN



Coronary DCB  
AcoArt Camellia®



## Key Updates on Collaboration with BSC: R&D

In 2025, Acotec and BSC entered into R&D Services Agreement for collaborative partnership in R&D, focusing on the co-development of products.

**ACOTEC**  
先瑞达

**Boston  
Scientific**

Collaborative Design Input

Collaborative Design Input

Product Development

Confirming Product Design

Product Registration

Confirming Finalized Product

### Product Commercialization

Upon market launch of co-development products, BSC holds the global commercialization rights for these products.

**03**

# Product Commercialization

For Investors' Reference Only

We maintained market competitiveness through reliable products and first-mover advantages

TRUSTED INNOVATION  
FOR LIFE


Peripheral DCB products have been listed in over 2,500 hospitals



**SFA DCB**  
AcoArt Orchid® & Dhalia®

#### Market Strategy:

- Acotec's SFA DCB was the first approved product of its kind in China. Leveraging this early-mover advantage and its outstanding clinical performance, we have established a strong competitive edge and maintain our leadership in market share.




#### VBP:

- Winning in Hebei+ Sanming VBP** accelerates the hospital listing and coverage, driving rapid growth in clinical implants. SFA DCB was also recently included in the Hebei renewal tender.
- We won bids in the Henan provincial VBP in 2025.**

#### Market Strategy:

- As the exclusive product provider, we are advancing domestic BTK treatment standards through our comprehensive one-stop therapeutic device portfolio.



**BTK DCB**  
AcoArt Tulip® & Litos®



**We secured rapid market expansion through targeted penetration and clinical adoption support**

**TRUSTED INNOVATION  
FOR LIFE**

**Venous intervention products have been listed in over 2,500 hospitals**




## Peripheral Aspiration System AcoStream®

### Market Strategy:

- We have established a complete product matrix to enhance the clinical efficacy of our aspiration systems.
- Leveraging our first-mover advantage, we have extensively penetrated the lower-tier markets, addressing the urgent demand particularly in Tier 3 and 4 cities.

### VBP:

- **Winning the bid in Henan's VBP in 2023** accelerated product admissions in hospitals and increased implant volumes.
- **We won bids in the Henan provincial VBP again in 2025.**



## Peripheral RFA System AcoArt Cedar®



### Market Strategy:

- We are continuously expanding our hospital coverage, conducting training programs to enhance physicians' skills and knowledge, and promoting therapy transformation.

### VBP:

- **Winning the bid in Henan's VBP in 2023** accelerated product admissions in hospitals and increased implanting volumes.
- **We won bids in the Henan provincial VBP again in 2025.**



# AcoArt Verbena: Addressing Unmet Clinical Needs with Robust Efficacy to Drive Growth


TRUSTED INNOVATION  
FOR LIFE

## AcoArt Verbena®

椎动脉紫杉醇涂层球囊扩张导管

介入无植入 守护新“涂”径


经典载药技术的又一大应用  
介入无植入, 为椎动脉开口处狭窄患者提供新的临床选择



50,000  
procedures/year

- Current annual vertebral artery origin stenosis (VAOS) intervention volume is approximately 50,000, growing at a rate of 15% per year.
- Vessels on the non-dominant side (2–3 mm in diameter) are often too small for stenting – DCB addresses this unmet clinical need and unlocks new market potential.

Ischemic strokes account for **70.2%** of all strokes



- Stroke is the second leading cause of death and the third leading cause of disability globally.
- According to epidemiological survey data released by the Chinese Stroke Association, **there are 3.3 million new stroke cases annually in China.** Between 25% and 40% of ischemic strokes occur in the posterior circulation, and among these, 9% to 33% involve VAO stenosis or occlusion. Therefore, among the annual new stroke cases, an estimated **150,000 to 200,000 patients present with VAOS.**
- Treating VAO stenosis is significant for stroke prevention.**

### The vertebral artery DCB has demonstrated outstanding superiority

#### Clinical Trial

**Treatment Group**  
AcoArt Verbena® DCB

**Control Group**  
Apollo® Stent



**180 patients**  
1:1 allocate to the DCB group and the Stent group.



**17**  
research centers



**3-5mm**  
Target lesion reference vessel diameter




**≥70%**  
Target lesion stenosis degree

#### Primary Study Endpoints



**Superior efficacy clinical trial results**

#### The restenosis rate at 12-month follow-up





# With Approvals of Our Coronary Paclitaxel and Sirolimus DCBs, We Now Offer a **TRUSTED INNOVATION** Comprehensive Portfolio and a Strong Commercial Outlook **FOR LIFE**

## A Comprehensive Product Matrix: Featuring Access, Vessel Preparation, and Therapeutic Devices



Coronary Paclitaxel DCB  
AcoArt Camellia®



Coronary Sirolimus DCB  
AcoArt Canna®



Semi-compliant PTCA  
Balloon  
YAN



Coronary CTO Recanalization  
Balloon  
RT-Zero®



Coronary High-Pressure PTCA  
Balloon  
YIYAN



Coronary CTO Antegrade  
Micro-Catheter  
Vericor-14®




Coronary CTO  
Retrograde Micro-Catheter  
Vericor-RS®



Coronary Micro-Catheter  
Vericor-S2®

**1,600K+**/Annual Procedures

A large procedural volume base + high growth rate signifies broad market potential.



### Supply Chain Advantages

Supply Chain Strength Ensures Acotec's Product Quality, Cost Control, and Sustained Supply

**04**

# **R&D, Product Approvals, and Manufacturing Status**


For Investors' Reference Only

# 2025: 9 Products Launched, Marking a Record High in Approvals

TRUSTED INNOVATION  
FOR LIFE

## 9 New Approvals (2025/1/1-2025/8/31)

### Neurology



**Vertebral DCB  
AcoArt Verbena®**

### Cardiology



**Coronary Sirolimus DCB  
AcoArt Canna®**



**Coronary Micro-Catheter  
Vericor-S2®**

### Vascular Surgery



**Pressure-Controlled  
Connector**



**Embolus Removal  
Device for Peripheral  
Thrombus Aspiration  
Catheter**



**Peripheral Scoring  
Balloon  
E-Peridge®**



**Peripheral Ultra-High  
Pressure Balloon  
Armoni-HP®**



**Peripheral  
Micro  
Guidewire**



2D



3D

**Peripheral Controlled  
Mechanically  
Detachable Fibered  
Coil**

# Diverse Tech Accumulation: Building a Multi-Specialty Portfolio, Boosting R&D & Achieving Scale

TRUSTED INNOVATION  
FOR LIFE

## Multi-Technology Matrix

Drug-coating Technology

Aspiration Platform Technology

Polymer Material Technology

RFA Technology

Metal Processing

Fiber Composite Technology

Plasma Welding

.....

30

Approved Products

4

Department Coverage

29

Overseas countries converge



China's First Approved Product or the First Approved Domestic Brand Product


# The BTK DCB AcoArt Litos® : Multiple clinical trial sites activated in U.S./Europe, TRUSTED INNOVATION FOR LIFE



**AcoArt Litos®**



The IDE application received FDA approval on Nov 29, 2023



Litos was granted designation as Breakthrough Device from FDA in 2019

✓ US and European sites simultaneously activated

✓ Patient enrollment progressing systematically

✓ US BTK surgery volume is 150,000/year, indicating broad application prospects for DCB



**FIRST COAST  
CARDIOVASCULAR  
INSTITUTE**



**COLUMBIA  
UNIVERSITY**



**SOUTH CHARLOTTE  
GENERAL &  
VASCULAR SURGERY**

**UT Southwestern  
Medical Center**

- We have partnered with several renowned sites and PIs in the peripheral vascular disease field in the U.S.



- Acotec BTK DCB obtained CE Mark in 2014 and has been clinically applied in Europe for nearly 10 years. European PIs are familiar with the product and have extensive clinical experience.

Enrollment in progress





# Expanding R&D and Production Across Core Industrial Chain, Building an Innovation Moat

TRUSTED INNOVATION  
FOR LIFE

## Enhancing R&D Efficiency

- We utilize our in-house technology to expedite prototyping. This allows for more trial-and-error opportunities, enhancing R&D efficiency while maintaining quality.



## Self-sufficiency in producing raw materials

- Our self-produced raw materials have achieved the desired quality level, and we are gradually replacing some of the originally imported materials with our own.



## Reduce R&D and production costs

- The efficient R&D, as well as a high proportion of self-produced raw materials, have helped us achieve cost reduction and efficiency improvement.



Laser Cutting



Microsphere Synthesis Technology



Ultra-Slippery Hydrophilic Coating Technology (Metal & Polymer)



Active Medical Device Technology



Laser Welding



Extrusion & Balloon Forming



Fiber Composite Technology



Plasma Welding Technology



Braiding

.....



# Dual - Base Synergistic Production Strategy: Sufficient Capacity for Growing Market Demand and OEM Business

TRUSTED INNOVATION  
FOR LIFE

**4+M** Units/Year

Sufficient to Meet Growing Market Demand and Potential OEM Needs

The gross floor area of production facilities

30,800m<sup>2</sup>

BEIJING

8,126m<sup>2</sup>

SHENZHEN



**05**

**Q&A**

For Investors' Reference Only



**THANKS!**

谢谢!

# Products and Pipeline-Full Product Portfolio (1/2)

TRUSTED INNOVATION  
FOR LIFE

Department	Products and Product Candidates	Indications / Applications	Key Technologies	Phase							Upcoming Milestone
				Area	Pre-clinical Studies		Clinical Studies		Registration		
Vascular Surgery	AcoArt Orchid® & Dhalia®/Orchid Plus★ <sup>Note 1</sup>	Superficial femoral artery (SFA) and popliteal artery (PPA) disease	Drug coating technology	China	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	NMPA Approval★	/
				EU	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	CE★	/
	AcoArt Tulip® & Litos®★	Below-the-knee (BTK) artery disease	Drug coating technology	China	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	NMPA Approval★	/
				EU	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	CE★	/
				U.S.	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>			
	AcoArt Iris® & Jasmin®	PTA Balloon applied in PTA procedure	Polymer materials	China	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	NMPA Approval★	/
	AcoArt Lily® & Rosmarin®	PTA Balloon applied in PTA procedure	Polymer materials	China	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	NMPA Approval★	/
	Peripheral Aspiration System (AcoStream®)▲	DVT, ALI	Aspiration platform	China	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	Exempted from clinical trial	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	NMPA Approval★	/
	Radiofrequency Ablation System (AcoArt Cedar®)	Saphenous varicose veins	RF platform	China	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	NMPA Approval★	/
	Peripheral Support Catheter (Vericor®)▲	Peripheral CTO lesion	Polymer materials	China	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	Exempted from clinical trial	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	NMPA Approval★	/
				U.S.	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>		<div><div></div><div></div><div></div></div>	FDA Approval★	/	
				Brazil	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>		<div><div></div><div></div><div></div></div>	ANVISA Approval★	/	
				Thailand	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>		<div><div></div><div></div><div></div></div>	TFDA Approval★	/	
				Japan	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>		<div><div></div><div></div><div></div></div>	MHLW Approval★	/	
	PTA Balloon (P-Conic®)	PTA	Polymer materials	China	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	Exempted from clinical trial	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	NMPA Approval★	/
	2nd Gen Peripheral Aspiration System (2 <sup>nd</sup> Generation AcoStream®)▲	DVT, ALI	Aspiration platform	China	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	Exempted from clinical trial	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	NMPA Approval★	/
	Introducer Sheath Set Acotrace	PTA	Polymer materials	China	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	Exempted from clinical trial	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	NMPA Approval★	/
	Delivery Catheter for Aspiration Catheter	DVT	Polymer materials	China	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	Exempted from clinical trial	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	NMPA Approval★	/
	Pressure-Controlled Connector▲	DVT	Aspiration platform	China	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	Exempted from clinical trial	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	BMPA Approval★	/
	Embolus Removal Device for Peripheral Thrombus Aspiration Catheter	DVT	Aspiration platform	China	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	NMPA Approval★	/
	Peripheral Scoring Balloon (E-Peridge®)	PTA	Polymer materials	China	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	NMPA Approval★	/
	Peripheral Ultra-High Pressure Balloon (Armoni-HP®)	CTO	Polymer materials	China	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	NMPA Approval★	/
	Micro Guidewire▲	PTA	Polymer materials	China	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	Exempted from clinical trial	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	BMPA Approval★	/
	Peripheral Controlled Mechanically Detachable Fibred Coil	Embolization	Polymer materials	China	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	NMPA Approval★	/
	Lower Limb Sirolimus DCB	SFA and PPA disease	Drug coating technology	China	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>	<div><div></div><div></div><div></div></div>		2026

★Core product

☆ Indication expansion of core product

★Commercialization

▲ Exempted from clinical trial requirements in accordance with the Catalogue of Medical Device Exempted from Clinical Trials (《關於進行臨床試驗醫療器械目錄》) promulgated by the NMPA, as amended.

Note 1: We have been continuously improving the performance of AcoArt Orchid® & Dhalia®. As advised by NMPA and as part of our business strategy, we decided not to register Orchid Plus as a separate product. Alternatively, we applied to register Orchid Plus as an upgrade version of AcoArt Orchid® & Dhalia® with improved delivery balloon catheter system, and received the revised NMPA approval for AcoArt Orchid®& Dhalia® in November 2021.

# Products and Pipeline-Full Product Portfolio (2/2)

TRUSTED INNOVATION  
FOR LIFE

Department	Products and Product Candidates	Indications / Applications	Key Technologies	Phase						Upcoming Milestone		
				Area	Pre-clinical Studies		Clinical Studies	Registration				
Cardiology	Semi-compliant PTCA Balloon (YAN) ▲	PTCA	Polymer materials	China	<div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div>	✓	Exempted from clinical trial	<div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div>	✓	NMPA Approval★	/	
	Coronary CTO Recanalization Balloon (RT-Zero®)▲	Coronary CTO	Polymer materials	China	<div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div>	✓	Exempted from clinical trial	<div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div>	✓	NMPA Approval★	/	
	Coronary CTO Antegrade Micro-Catheter (Vericor-14®) ▲	Coronary CTO	Polymer materials	China	<div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div>	✓	Exempted from clinical trial	<div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div>	✓	NMPA Approval★	/	
				Japan	<div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div>	✓		<div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div>	✓	MHLW Approval★	/	
				Thailand	<div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div>	✓		<div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div>	✓	TFDA Approval★	/	
	Coronary Retrograde Micro-Catheter (Vericor-RS®) ▲	Coronary CTO	Polymer materials	China	<div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div>	✓	Exempted from clinical trial	<div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div>	✓	NMPA Approval★		
	Coronary High-Pressure Balloon (YIYAN) ▲	PTCA	Polymer materials	China	<div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div>	✓	Exempted from clinical trial	<div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div>	✓	NMPA Approval★		
	Coronary Paclitaxel DCB (AcoArt Camellia®)	Coronary small vessel diseases	Drug coating technology	China	<div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div>	✓	<div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div>	⬛	<div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div>	✓	NMPA Approval★	
	Cardiac Valve Balloon (RunFlow®)	TAVR	Polymer materials	China	<div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div>	✓	<div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div>	⬛	<div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div>	✓	NMPA Approval★	
	Coronary Micro-Catheter (Vericor-S2®)▲	PCI	Polymer materials	China	<div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div>	✓	Exempted from clinical trial	<div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div>	✓	NMPA Approval★	/	
Coronary Sirolimus DCB (AcoArt Canna®)	Bifurcation lesions	Drug coating technology	China	<div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div>	✓	<div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div>	⬛	<div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div>	✓	NMPA Approval★	/	
Coronary IVL System	Coronary lesion calcium	Polymer materials	China	<div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div>	✓	<div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div>	⊙	<div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div>	⊙		2027	
Nephrology	AcoArt Orchid®& Dhalia®/Orchid Plus☆(DCB)	Arteriovenous fistula stenosis	Drug coating technology	China	<div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div>	✓	<div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div>	⬛	<div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div>	✓	NMPA Approval★	/
	Paclitaxel Coated High-pressure Balloon (ACOART AVENS®)	AVF PTA procedure	Drug coating technology	China	<div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div>	✓	<div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div>	⬛	<div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div>	✓	NMPA Approval★	/
	AV Scoring Balloon (Peridge®)	AVF PTA procedure	Polymer materials	China	<div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div>	✓	<div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div>	⬛	<div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div>	✓	NMPA Approval★	/
Neurology	Intracranial PTA Balloon (NEO-Skater®)▲	Intracranial PTA procedure	Polymer materials	China	<div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div>	✓	Exempted from clinical trial	<div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div>	✓	NMPA Approval★	/	
	AcoArt Verbena® (DCB)	Vertebral atherosclerotic stenosis	Drug coating technology	China	<div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div>	✓	<div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div>	⬛	<div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div>	✓	NMPA Approval★	/

★Core product

☆ Indication expansion of core product

★Commercialization

▲ Exempted from clinical trial requirements in accordance with the Catalogue of Medical Device Exempted from Clinical Trials (免於進行臨床試驗醫療器械目錄) promulgated by the NMPA, as amended.